Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingjiao Zhang

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center|August 8, 2024
Establishment of Prognostic Nomogram for Male Breast Cancer Patients: A Surveillance, Epidemiology and End Results Database AnalysisZhongjing Ma, Mengyao Xu, Jingjiao Zhang, et al.
Chempluschem|August 8, 2024
Bio-Inspired Adaptive and Responsive Protein-Based MaterialsYingying Zhang, Qi Zhao, Jingjiao Zhang, et al.
Scientific Reports|July 2, 2013
Enlarging photovoltaic effect: combination of classic photoelectric and ferroelectric photovoltaic effectsJingjiao Zhang, Xiaodong Su, Mingrong Shen, et al.
Frontiers in Oncology|December 11, 2023
Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature reviewYang Li, Jingjiao Zhang, Zhengang Cai, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cancer Control : Journal of the Moffitt Cancer Center|August 8, 2024
Establishment of Prognostic Nomogram for Male Breast Cancer Patients: A Surveillance, Epidemiology and End Results Database AnalysisZhongjing Ma, Mengyao Xu, Jingjiao Zhang, et al.
Chempluschem|August 8, 2024
Bio-Inspired Adaptive and Responsive Protein-Based MaterialsYingying Zhang, Qi Zhao, Jingjiao Zhang, et al.
Scientific Reports|July 2, 2013
Enlarging photovoltaic effect: combination of classic photoelectric and ferroelectric photovoltaic effectsJingjiao Zhang, Xiaodong Su, Mingrong Shen, et al.
Frontiers in Oncology|December 11, 2023
Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature reviewYang Li, Jingjiao Zhang, Zhengang Cai, et al.
Pageof 1